Tumor Testing Approach for Pediatric Cancer

Not yet recruiting at 1 trial location
SD
Overseen BySteven Dubois, MD,MS
Age: < 65
Sex: Any
Trial Phase: Academic
Sponsor: Dana-Farber Cancer Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is looking to learn whether a tumor testing approach can feasibly measure antibody-drug conjugate (ADC) target proteins in children and young adults with relapsed or refractory solid tumors or central nervous system (CNS) tumors.

The tumor testing approach is a two-step tumor profiling process of:

* Screening with bulk RNA sequencing to see which ADC target genes are turned on in the tumor.

* Confirmatory immunohistochemistry (IHC) for targets that show positive expression on the RNA screen, to confirm protein expression.

Who Is on the Research Team?

SD

Steven Dubois, MD,MS

Principal Investigator

Dana-Farber Cancer Institute

Are You a Good Fit for This Trial?

This trial is for children and young adults who have solid tumors or brain/CNS tumors that have come back or haven't responded to treatment.

Inclusion Criteria

Prospective Cohort: Life expectancy of at least 12 weeks at enrollment
I have enough tumor tissue samples available for required lab tests.
Prospective Cohort: Informed consent for adults or parental permission with assent for minors
See 6 more

Exclusion Criteria

Prospective Cohort: Incarcerated individuals
Prospective Cohort: Pregnant women
I am an adult who cannot give consent for myself.

What Are the Treatments Tested in This Trial?

Trial Overview

Researchers are testing if they can reliably measure certain proteins in tumor samples using a two-step process: first, checking gene activity with RNA sequencing, then confirming protein presence with immunohistochemistry (IHC).

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Retrospective CohortExperimental Treatment1 Intervention
Group II: Prospective CohortExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute

Lead Sponsor

Trials
1,128
Recruited
382,000+

B+ Foundation

Collaborator